CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study
Year: 2021
Type: conference-abstract
Authors: Jorge E. Cortes, Timothy P. Hughes, Michael J. Mauro, Andreas Hochhaus, Delphine Réa, Yeow-Tee Goh, J.J.W.M. Janssen, Michael C. Heinrich, Moshe Talpaz, Gabriel Etienne, Massimo Breccia, Michael Deininger, Philipp le Coutre, Fabian Lang, Fotis Polydoros, Silvia Cacciatore, Laura Stenson, Dong-Wook Kim
Institutions: South Australian Health and Medical Research Institute, The University of Adelaide, Memorial Sloan Kettering Cancer Center, Jena University Hospital, Hôpital Saint-Louis, Singapore General Hospital, Amsterdam UMC Location Vrije Universiteit Amsterdam, VA Portland Health Care System, OHSU Knight Cancer Institute, U-M Rogel Cancer Center, Université de Bordeaux, Sapienza University of Rome, Huntsman Cancer Institute, Charité - Universitätsmedizin Berlin, Goethe University Frankfurt, University Hospital Frankfurt, Novartis (Switzerland), Novartis (Ireland), The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3196601917